Safe,
trusted care

Dr. Benjamin Weinstein is the Chair of Psychiatry and Chief of Service at Houston Methodist Hospital, ranked by U.S. News & World Report as the #1 hospital in Texas, and he is the C. James and Carole Walter Looke Presidential Distinguished Centennial Clinical Academic Scholar in Behavioral Health. He is also a Clinical Professor at UT McGovern Medical School. 
‍

His life’s work has been to treat patients with complex and severe mental illness. Dr. Weinstein is passionate about increasing access to effective mental health treatments, and he believes Mindbloom can play a transformative role in psychiatry by safely providing industry-leading outcomes and increasing affordability of ketamine treatment to people anywhere in the country. Dr. Weinstein aspires to increase awareness of this promising treatment and accelerate insurance coverage. 
‍

Dr. Weinstein is board certified in Psychiatry and eligible Neurology with 23+ years of experience in the medical field. He graduated from the Medical University Of South Carolina medical school and later served on faculty, where he won multiple awards for teaching and clinical excellence. Prior to joining Houston Methodist, he served as Assessment Division Director at The Menninger Clinic and Associate Professor at Baylor College of Medicine.

Dr. Gazzaley is a neuroscientist, neurologist, inventor, and entrepreneur.  He is the David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco.  He is also the Founder and Executive Director of Neuroscape, a translational neuroscience center at UCSF engaged in technology creation and scientific research.  At Neuroscape, Dr. Gazzaley designs and develops novel brain assessment and optimization tools to impact education, wellness, and medicine practices.

‍

In addition to his work at UCSF, Dr. Gazzaley is Co-Founder and Chief Science Advisor of Akili Interactive, a company developing therapeutic video games, and is also the Co-Founder and Chief Scientist of JAZZ Venture Partners, a venture capital firm that invests in experiential technology to improve human performance.  Dr. Gazzaley has served as a scientific advisor to more than a dozen companies including Apple, GE, Nielsen, Deloitte, Janssen, and PepsiCo, as well as the President’s Council on Fitness, Sports & Nutrition. He has been issued numerous patents, including for his invention of the first video game ever approved by the FDA.  Dr. Gazzaley is a frequent speaker and author on topics in science and mental health, and is a Trustee and Science Council Member and Fellow of the California Academy of Sciences.

‍

Dr. Gazzaley obtained an M.D. and a Ph.D. in Neuroscience at the Mount Sinai School of Medicine.  He completed a Neurology residency at the University of Pennsylvania, and postdoctoral training in cognitive neuroscience at the University of California, Berkeley.

Kristin represents the voice of the Psychiatric Nurse Practitioner at Mindbloom. She is a board-certified Psychiatric NP with over 15 years of experience working in mental health. She spent nearly a decade in the California state hospital system working with some of our nation’s most vulnerable. Driven by her passion to increase access to mental care, she’s been at the forefront of integrating technology into care delivery models with early roles at cutting edge health-tech start-ups including Oscar and Call9, and by bringing telemental health to the Brooklyn VA Hospital.

‍

As a clinician, Kristin is a proponent for alternative forms of treatment such as psychedelic medicines and treated the first cohort of clients at Mindbloom. Her approach to treatment is one that is client-centered driven by the ethos of harm reduction. In addition to her clinical practice, she is a guest lecturer at NYU-School of Nursing on topics such as psychedelic therapy and substance use disorders.

‍

Kristin graduated from NYU’s Psychiatric Nurse Practitioner program and specialty track in substance use and addictions where she received the distinguished student award. She is currently pursuing her DNP at Rush University.

Dr. Alok Madan is Vice Chairman, Department of Psychiatry and John S. Dunn Foundation Distinguished Centennial Clinical Academic Scholar in Behavioral Health at Houston Methodist. He is also Professor of Psychology in Neurosurgery at Houston Methodist Academic Institute and Professor of Psychology in Clinical Psychiatry at Weill Cornell Medical College.

He joined Mindbloom’s Medical Advisory Board after reviewing the remarkable clinical outcomes that our clients have experienced from remote ketamine therapy, and he is excited to co-author an upcoming clinical study using Mindbloom’s outcomes data to further advance research and increase access to this innovative mental health treatment.

Dr. Madan has extensive experience in the implementation and evaluation of programs to improve care quality. He has led efforts to improve the safety of inpatient psychiatric care, implement outcomes assessment systems, evaluate the effectiveness of integrated psychiatric treatment for individuals with severe neuropsychiatric illness as well as identify biomarkers of illness and response to treatment.

He earned his doctorate in clinical psychology and master of public health degrees from the University of Alabama at Birmingham. He has been involved in formal training, direct patient care, clinic management and research to improve neuropsychiatric care for 15+ years. Prior to joining Houston Methodist, he was an Associate Professor at Medical University of South Carolina and Baylor College of Medicine and was a McNair Scholar and Senior Psychologist at The Menninger Clinic.

Dr. Leonardo Vando is a Board Certified Psychiatrist and Addiction Psychiatrist with over 15 years of experience in treating the full spectrum of psychiatric and addictive disorders. He specializes in treating complex conditions requiring integration of genetic, metabolic, cultural and psychosocial data points in order to achieve reduction of symptoms and promote healing.

Dr. Vando has been at the forefront of ketamine use in clinical practice, developing intramuscular protocols to achieve rapid results and minimize adverse events for treatment-resistant depression and addictive disorders, with a focus on increasing access to treatment in low income communities. He is also contributing to the field of psychedelic medicine through his work and research on microdosing for mental illness.

He attended Sacred Heart University as a chemistry undergrad and received a medical degree from Ponce School of Medicine. He trained as a psychiatrist and addictionologist in NYC’s Beth Israel Medical Center. He currently resides in New York, where he has worked in private practice for over a decade.